PureTech’s LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy VolunteersPosted by MMP News AuthorOn November 18, 2023

[ad_1]


BOSTON–(BUSINESS WIRE)–PureTech’s LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers

[ad_2]

Source link